SCHEDULE: Mallick Boosts Nautilus Biotech Stake to 17.6%

Parag Mallick, a key insider, has increased his beneficial ownership in Nautilus Biotechnology, Inc. to 17.6% through a recent option grant.

Summary

• Parag Mallick beneficially owns an aggregate of 22,557,411 shares of Nautilus Biotechnology, Inc. common stock.
• This ownership represents 17.6% of the Issuer's outstanding shares, calculated based on 126,564,473 shares outstanding as of February 19, 2026, plus 1,864,019 shares issuable from options held by Mallick.
• Mallick's holdings include 20,493,392 shares directly owned, 1,864,019 shares issuable upon exercise of options, and 200,000 shares held by The Dream Finder Foundation.
• Of the options, 1,234,018 shares are vested and exercisable within 60 days of March 2, 2026.
• On March 2, 2026, Mallick was granted an option to purchase an additional 280,000 shares of the Issuer's Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as increased insider ownership, particularly through option grants, generally reflects continued confidence from key management in the company's future, which is a positive for investor sentiment.

Positives

• Increased beneficial ownership by a key insider (Parag Mallick) to 17.6% signals continued confidence in the company's future prospects.
• A recent grant of options to purchase 280,000 shares indicates ongoing compensation and aligns management's interests with those of shareholders.

Risks

• Unvested options are subject to the Reporting Person's continued service, posing a risk of forfeiture if service ceases prematurely.
• The accelerated vesting clause tied to a change in control and termination events introduces a specific risk related to management retention during such periods.

Future Outlook

The filing does not provide a general future outlook for the company, but it details the vesting schedule for unvested options, which are subject to the Reporting Person's continued service over time. Additionally, 100% of unvested shares will immediately vest under specific termination conditions during a change in control period.

Industry Context

StockSavvy.ai notes that significant insider ownership, especially by founders or key executives like Parag Mallick, is often viewed positively in the biotechnology sector as it aligns management's interests with those of long-term shareholders. This continued accumulation of shares, even through option grants, can signal confidence in the company's long-term prospects, which is crucial in a high-risk, high-reward industry like biotech.

Comparison to Industry Standards

• Insider ownership percentages vary widely across the biotech industry, but a 17.6% stake by a key individual like Parag Mallick is substantial and generally considered a strong indicator of commitment, often exceeding the average for executives in more mature, larger-cap biotech firms.
• For example, compared to early-stage biotech companies where founders often retain significant stakes (e.g., Moderna's CEO Stéphane Bancel held around 8% at IPO), Mallick's stake is robust.
• The structure of option grants with performance-based or time-based vesting is standard practice across the industry to incentivize long-term performance and retention.

Related Party Transactions

• The Dream Finder Foundation, over which Dr. Mallick and his spouse share voting and dispositive power, holds 200,000 shares of Common Stock.

Stakeholder Impact

• Shareholders: Increased insider ownership can be seen as a positive alignment of interests, potentially boosting investor confidence.
• Employees: The vesting schedule for options, tied to continued service, incentivizes long-term commitment from the Reporting Person.

Next Steps

• Continued service by the Reporting Person for unvested options to vest over time.
• Potential future exercises of vested options.

Key Dates

Recommendation

While the increased insider ownership by Parag Mallick is a positive signal of confidence, this Schedule 13D amendment primarily reports a routine change in beneficial ownership due to an option grant. It does not contain new operational or financial performance data that would warrant a change in investment thesis. Investors should hold their position and await further fundamental updates on the company's business performance and strategic developments.

Keywords

Nautilus Biotechnology, Parag Mallick, Schedule 13D, Beneficial Ownership, Insider Ownership, Stock Options, Biotechnology, SEC Filing, Corporate Governance